Connect Sign InBehind the Making of MLL: Vision and Mission
Dr. Haferlach discusses the making and challenges of launching and growing a clinical laboratory and how the Munich Leukemia Laboratory helps set the standards in the diagnosis of hematological neoplasms through research, innovation, and the integration of current and cutting edge knowledge. He emphasizes comprehensive and personalized diagnostics, aiming to improve and extend patients' lives.
Dr. Torsten Haferlach is a German hematologist and professor. He is the head of the Munich Leukemia Laboratory (MLL) in Munich, Germany, which specializes in diagnostic genetics and research related to leukemia and lymphoma. Dr. Haferlach's main research focuses on molecular mechanisms in hematological malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and acute lymphoblastic leukemia (ALL). He has authored or co-authored hundreds of peer-reviewed publications and has been involved with several major studies and clinical trials related to genetic biomarkers and risk stratification in leukemia. He is a central contributor and author to the WHO classification and serves on the editorial boards of several hematology/oncology journals.
